Filter
105
Filtered Results: 105
Text search:
Oladapo,
O.T
Featured
Recommendations
16
New Publications
33
Language
Document type
Guidelines
48
No document type
37
Manuals
9
Studies & Reports
8
Training Material
1
Infographics
1
Strategic & Response Plan
1
Countries / Regions
Global
7
Nigeria
5
Brazil
4
Guinea-Bissau
2
Mozambique
2
Angola
2
Cameroon
1
Uganda
1
Zimbabwe
1
Nepal
1
Malawi
1
Paraguay
1
Africa
1
Russia
1
Authors & Publishers
Publication Years
Category
Women & Child Health
46
Clinical Guidelines
37
Countries
17
Public Health
8
Key Resources
1
Toolboxes
Caregiver
18
COVID-19
10
Zika
6
HIV
4
TB
4
Global Health Education
2
AMR
2
Planetary Health
2
Ebola
1
Mental Health
1
WHO Recommendations 2018 Update
The primary audience for these recommendations includes health professionals who are responsible for developing national and local health care guidelines and protoco...
The recommendation in this document thus supersedes the previous WHO recommendation for ...he prevention of PPH as published in the 2012 guideline
The primary audience of these recommendations includes healthcare providers who are responsible for developing national and local health protocols (particularly ...hose related to hypertensive disorders of pregnancy), and those directly providing care to pregnant women and their newborns, including midwives, nurses, general medical practitioners, obstetricians, obstetric physicians, managers of maternal and child health programmes, and relevant staff in ministries of health, in all settings.
The WHO Living guideline: Drugs to prevent COVID-19 contains the Organization’s most up-to-dat...
Guidelines for the management of pregnant and breastfeeding women in the context of Ebola virus disease
recommended
To save the lives of mothers and their babies, mitigate complications, and limit the spread of d...
Web annex 5: Oxytocin and ergometrine versus placebo or no treatment
Evidence to decision framework
WHO Living guideline: Drugs to prevent COVID-19
recommended
Interim guidance 2 march 2021
Current use of drugs to prevent COVID-19 is variable, reflecting large-scale uncertainty. Numerous randomized trials of many different drugs are underway ...o inform practice. This first version of the Drugs to prevent COVID-19: A WHO living guideline contains new information and a recommendation on hydroxychloroquine. It follows the publication of six trials synthesized in a living network meta-analysis (NMA).
Web annex 6: Injectable prostaglandins versus
placebo or no treatment
Evidence to Decision Framework
The recommendation in this document thus supersedes the previous WHO recommendation for ...he prevention of PPH as published in the 2012 guideline, WHO recommendations for the prevention and treatment of postpartum haemorrhage.
The primary audience for this guideline includes health-care professionals who are responsible for developing national and local health-care protocols and policies, as well as managers of maternal a...
BMJ,Dodd PJ, et al. Thorax 2017;72:559–575. doi:10.1136/thoraxjnl-2016-209421
The HEARTS technical package provides a strategic approach to improving cardiovascular health in countries. It comprises six modules and an impleme...
Improvements in water sanitation and hygiene (WASH) and wastewater management in all sectors are critical elements of preventing infections and reducing the spread of antimicrobial resistance (AMR) as identified in ...he Global Action Plan to combat AMR. Yet, at present, WASH and wastewater management actors and improvement actions are under-represented in AMR multi-stakeholder platforms and national action plans (NAPs). This WHO/FAO/OIE technical brief on WASH and wastewater management to reduce the spread of AMR provides a summary of evidence and rationale for WASH and wastewater actions within AMR NAPs and sector specific policy to combat AMR. Evidence and actions are presented in the domains of; coordination and leadership, households and communities, health care facilities, animal and plant production, manufacturing of antimicrobials, and surveillance and research.
Web annex 2: Carbetocin versus placebo or no treatment
Evidence to decision framework
Ces recommandations ont été élaborées dans le cadre de la mission de l’Organisation mondiale de la Santé de fournir des orientations normatives à ses États-membres. L’objectif de ce document est de formuler des recommandations fondées sur des données factuelles afin de faciliter l’acc...
This toolkit was developed to provide detailed information and resources to support implementati...
